Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

RECEIVED. SECRETOBBYING REPOR

07 FEB 15 PM 4: 38

3. Principal place of business (if different than line 2) City State Zip Code - Cou 4a. Contact Name b. Telephone Number c. E-mail 5. Sen International Number marguerite.baxte4@novartis.com 3116 7. Client Name Self 6. Hotel	NOVARTIS VACCINES AND DIAGNOSTICS, INC.					
3. Principal place of business (if different than line 2) City State Zip Code Cou 4a. Contact Name b. Telephone Number International Number Ms. MARGUERITE D. BAXTER (202) 962-8640 marguerite.baxte4@novartis.com 3116 7. Client Name Self 6. Ho NOVARTIS VACCINES AND DIAGNOSTICS, INC. 385- TYPE OF REPORT 8. Year 2006 Midyear (January1-June30) Year End (July 1-Dec 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date 11. No Lobbying Act INCOME OR EXPENSES - Complete Either Line 12 OR Line 13 12. Lobbying INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 State Sta						
4a. Contact Name Ms. MARGUERITE D. BAXTER (202) 962-8640	City WASHINGTON Sta	e DC	Zip Code	20005 -		Counti
International Number		e	Zip Code	-		Counti
NOVARTIS VACCINES AND DIAGNOSTICS, INC. TYPE OF REPORT 8. Year 2006 Midyear (January1-June30) Year End (July 1-Dec 2) Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date 11. No Lobbying Act INCOME OR EXPENSES - Complete Either Line 12 OR Line 13 12. Lobbying INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). **Supervise of this were:** Less than \$10,000 or more \$10,	International Num	er	xte4@novartis	i, çom		5. Senato 311690
D. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date 11. No Lobbying Activities for this reporting period was: 12. Lobbying 13. Organizations EXPENSE relating to lobbying activities for this reporting period was: Less than \$10,000 \$10,000 or more \$10,000 or	- ···					385430
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000						g Activi
Less than \$10,000	INCOME OR EXPENSES - Complete Either Lin	e 12 OR Line	13			g Activi
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indica accounting method. See instructions for description accounting method. See instructions for description accounting method. Reporting amounts using LDA definition activities on behalf of the client). Method B. Reporting amounts under section 6033 Internal Revenue Code Method C. Reporting amounts under section 1620	12. Lobbying INCOME relating to lobbying activities for this reporting period	EXPENSE		_	zations	
of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). Method A. Reporting amounts using LDA definition of the client	12. Lobbying INCOME relating to lobbying activities for this reporting period was:	EXPENSE were:	relating to lo	_	zations	
activities on behalf of the client). Method B. Reporting amounts under section 6033 Internal Revenue Code Method C. Reporting amounts under section 1620	12. Lobbying INCOME relating to lobbying activities for this reporting period was: Less than \$10,000	EXPENSE were:	relating to lo	obbying activ	zations	
Internal Revenue Code Method C. Reporting amounts under section 1620	INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 \$10,000 or more \$ Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all	EXPENSE were: Less than \$10.000 or mo	relating to lo	s 890,00	zations vities fo	r this re
Revenue Code	INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 \$10,000 or more Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying	EXPENSE were: Less than \$10. \$10,000 or mo 14. REPOR accounting to Method	relating to lo	\$ 890,00 Check instructions ag amounts usin	zations vities fo 00.00 box to i for dese	r this re
Signature Marquerite Saxten Date 02/	INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 \$10,000 or more Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying	EXPENSE were: Less than \$10.000 or mode accounting to the second of the	relating to lo	\$ 890,00 Check instructions amounts using amounts und Revenue Code ag amounts und	vities fo	r this re

		Marguerite Baxter VP and Head Global Public Affairs		
O	v5.0.0j		٠	Pa

15. General issue area co	de BUD Budget/A	ppropriations	(one per page)
		ppropriations	
16. Specific lobbying issu		· · · · · · · · · · · · · · · · · · ·	
preparedness and influenz HR 5631 FY 2007 Dept o		; Pandemic Influen:	Bill; House and Senate versions of bill r/t pand za Issues
17. House(s) of Congress	and Federal agencies	Check if None	✓ House ✓ Senate
Department of Health and Centers for Disease Cont			
18. Name of each individu	ual who acted as a lobbyist in t	this issue area	
_	Name	į	Covered Official Position (if applicable)
First Marguerite	Last Baxter	Suffix	
iviai guerrie	Daxtel		
19. Interest of each foreig	gn entity in the specific issues	s listed on line 16 at	bove

Client Name

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Registrant

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

ı 🧓	Printed Name and Title	Marguerite Baxter VP and Head Global Public Affairs	
1	v5.0.0j		Pa ₁

IR 4939 Eme	ergency Supplen uenza liability	nental Appropri	ations for FY 200	06; Section 2607	7 and Title IV, pa	indemic influen	za funding a
	active theoritis						
	•						
		•					

	Printed Name and Title	Marguerite Baxter VP and Head Global Public Affairs
in.	v5.0.0j	

S.969: A bill to amend the I Nation's ability to address pandemic Influenza	Public Health Se	rvice Act with	recnect to pres				
Nation's ability to address page		rvice Act with	rechect to pres				
		za.	respect to prej	paration for an i	nfluenza pand	emic, suppo	rted stre
17. House(s) of Congress a	nd Federal agen	cies 🗌	Check if None		✓ House	✓ Sena	te [
Centers for Disease Contro Department of Health and F							
18. Name of each individual	I who acted as a	lobbyist in this	s issue area	Covered (Official Position	on (if applic	 ahle)
Pirst	Last		Suffix	Covered	Jiliciai i ositii	on (ii appiic	1010)
Marguerite	Baxter						
		· · · · · · · · · · · · · · · · · · ·					
-							
				<u> </u>			
7 - 23 - 24 - 24 - 24 - 24 - 24 - 24 - 24					·		
			J.L.	<u> </u>			
			sted on linė 16		7 Check if N		

Client Name

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Registrant

e L	Printed Name and Title	Marguerite Baxter VP and Head Global Public Affairs	
is.	v5.0.0j		·····

	·
ADDENDUM for General Lobbying Issue Area: HCR - Health Issues	
S.1422; HR 881: A bill to amend the FDA Act to reduce human exposure to mercury through vaccines. It of the vaccine industry. HR 650: To establish reasonable legal reforms that will facilitate the manufacture of vital, life saving vac purposes. Lobbied in support of reasonal protections for vaccine manufacturers. HR 1297: To amend the Public Health Service Act with respect to the National Vaccine Injury Compensation for the interests of the vaccine industry. S.1828: Influenza Vaccine Security Act of 2005, lobbied in support of provisions to assure a strong dome S. 1821: Pandemic Preparedness and Response Act, lobbied in support of domestic pandemic prepared S. 375: Flu Protection Act of 2005, lobbied in support of domestic influenza provisions to stablize products. 969: Attacking Viral Influenza Across Nations Act of 2005, lobbied in support of influenza provisions S. 226 A bill to amend the Public Health Service Act to improve immunization Rates by increasing the support of influenza provisions S. 226 A bill to amend the Public Health Service Act to improve immunization Rates by increasing the support of influenza provisions S. 226 A bill to amend the Public Health Service Act to improve immunization Rates by increasing the support of the sup	ctines, and for othe ation Program. Lol estic vaccine industrandemic prepared ness. etion and supply.
General matters related to vaccines, the vaccine industry, pandemic preparedness and avian influenza	
,	

Pa

* · · · · · · · · · · · · · · · · · · ·	
1D v5.0.0j	Pa

S 662:	57 Access to	Live-Saving	Medicine Act	, vaccine dist	ribution and tr	acking provision	ns	
S 3673 S 1873	8 Pandemic 3 Biodefensi	and All Haza: e and Pandem	rds Preparedno ic Vaccine an	ess Act, pande d Drug Devel	emic influenza	vaccines 2006, tracking	and distribution	n of influenza va
			to raconic an	u Diug Devel	opinom rioi or	zooo, adoking	una albunoatioi	t of mindenza vi
								
						52 - Page 13 of :		

ngaged in lob nformation as 5. General is: 6. Specific lo IR 5122 Nation 2766 Depart IR 5533 Biod 3678 Pander 7. House(s) of Centers for Di Department of	sue area code obbying issues onal Defense Au timent of Defense defense and Panc mic and All Haz of Congress and isease Control ar f Health and Hur		s FY 200 for FY Drug De	orting period. ded. 7 2007 velopment Ac	Using a s	eparate pag	ge for each	code, j	Senate (
ngaged in lob nformation as 5. General is 6. Specific lo IR 5122 Nation 2766 Depart IR 5533 Biod 3678 Pander 7. House(s) of Centers for Di Department of	sue area code obbying issues onal Defense Au timent of Defense defense and Panc mic and All Haz of Congress and isease Control ar f Health and Hur	TOR Torts TOR Torts Authorization Act for e Authorization Act demic Vaccine and E ards Preparedness A Federal agencies Ind Prevention man Services The acted as a lobbying the acted acted as a lobbying the acted acted as a lobbying the acted	s FY 200 for FY Drug De	orting period. ded. 7 2007 velopment Ac Check if Non	Using a s	eparate pag	ge for each	code, j	Senate (
5. General is: 6. Specific lo 1R 5122 Nation 2766 Depart 1R 5533 Biod 3678 Pander 7. House(s) of Centers for Di Department of	s requested. Atta sue area code obbying issues onal Defense Au tment of Defens defense and Panc mic and All Haz of Congress and isease Control at f Health and Hur	TOR Torts uthorization Act for e Authorization Act demic Vaccine and E ards Preparedness A Federal agencies nd Prevention man Services who acted as a lobbyis Name Last	FY 200 for FY Drug Deact	7 2007 velopment Ac Check if Non	et of 2006	(oi	ne per page) House	V	Senate (
6. Specific looks 122 Nation 2766 Depart IR 5533 Biod 3678 Pander 7. House(s) of the content of	onal Defense Autment of Defense and Pancinic and All Hazof Congress and Isease Control at Health and Hur	uthorization Act for e Authorization Act demic Vaccine and E ards Preparedness A Federal agencies Ind Prevention man Services Pho acted as a lobbying Name Last	FY 200 for FY Drug De act	2007 velopment Ac Check if Non	ne	✓	House	✓	
IR 5122 Nation 2766 Depart IR 5533 Biodom 3678 Pander 7. House(s) of the content	onal Defense Autment of Defense and Pancemic and All Hazor Congress and isease Control are Health and Hur	e Authorization Act lemic Vaccine and E ards Preparedness A Federal agencies nd Prevention man Services Pho acted as a lobbying Name Last	for FY Drug De act	2007 velopment Ac Check if Non	ne	✓			
2766 Depart IR 5533 Biod 3678 Pander 7. House(s) of Centers for Di Department of 8. Name of earst	tment of Defense defense and Panc mic and All Haz of Congress and isease Control at f Health and Hur	e Authorization Act lemic Vaccine and E ards Preparedness A Federal agencies nd Prevention man Services Pho acted as a lobbying Name Last	for FY Drug De act	2007 velopment Ac Check if Non	ne	✓			
Centers for Di Department of 8. Name of earst	isease Control at f Health and Hur	nd Prevention man Services ho acted as a lobbying Name Last		s issue area					
Pepartment of 8. Name of earst	f Health and Hur	ho acted as a lobbying Name	st in this		Co	overed Offi	cial Positio	on (if a	pplicable)
rst	ach individual w	Name Last	st in this		Cc	overed Offi	cial Positio	on (if a	pplicable)
		Last		Suffix					
		7(Sunix		-	- ·····		
Aarguerite		Baxter	· · · · · · · · · · · · · · · · · · · 						
				[]	(8 1				
					<u> </u>				
			-			<u> </u>			
							•		
					1				
				[<u> </u>				
9. Interest of	f each foreign er	ntity in the specific i	issues li	sted on line 1	6 above	Į.	Check if N	lone	
	. .								
									
Printad Nam									

v5.0.0j

1973 Biodefe	ense and Pandemic	Vaccine and Dru	g Development A	ct of 2006		
obbied the ab	ove measures on su	istaining liability	protections for p	andemic influenza;	pandemic influ	enza issues
•						
						

v5,0.0j

Pa

Registrant NOVARTIS VACCINES AND DIA		S AND DIAGNO	STICS, INC.	Client Name	NOVARTIS VACCINES AND DIAGNOSTICS, INC.					
LOBBYIN	NG ACTIVITY. Sel	lect as many o	codes as necessar	y to reflect the	e general issu	e areas in whi	ch the registran	t		
	n lobbying on behalf on as requested. Attac			• •	ng a separate	page for each	code, provide			
15. Genera	al issue area code	МММ	Medicare/Medi	caid		one per page))			
16. Specif	ic lobbying issues									
HR 611 T	ax Relief and Health	Care Act of	2006, supported i	ssues related	to reimburser	ment for vacci	nes,			
17 Hayaa	(a) of Congress and	Endoral agan	oios 🗀 Ch	and if Nama		7 Hanas	[7] Samata			
17. House	(s) of Congress and	rederai agen	cies Che	eck if None		✓ House	✓ Senate			
18. Name	of each individual w	ho acted as a	lobbyist in this iss	sue area						
		Name	·		Covered (Official Position	on (if applicable	;)		
First		Last		Suffix						
Marguerit	е	Baxter								
		1								
			·····							
		<u> </u>			 					
					· · · · · · · · · · · · · · · · · · ·					
]								
19. Intere	st of each foreign en	tity in the sp	ecific issues listed	d on line 16 ab	oove [√	7 Check if N	Ione			
		•		<u> </u>						
Dulmard N	Standard Trials NA.: Filir	ng #1a592529	9-7a86-4045-9881-	9d4eab942d5	2 - Page 19 of	22				

rrinted Name and Title	Marguerne Daxter yr anu neau Giobai rubne Aliairs							
v5.0.0j								

nformation Update Page - Complete ONLY where registr:			 istratio	n inf	 Cormatio	mation has changed.						
20. Client new addre												
Address	53											
City				State		Zii	Code			 	Cou	
21. Client new princi	nal place of busin	ess (if different that	 . line 20									
City	pai piace oi ousii	less (ii different mai	1 1111 C 20	') State		7:-	Code				Cou	
·		. 1	•	Jian	-	— <i>-</i>	_				Cou.	
22. New General des	cription of chent	s ousiness or activit	ies									
LOBBYIST UPDA	TE		<u> </u>									
23. Name of each pre		ndividual who is no	longer	evne	ect to act	ac a lok	shviet for	r tha c	liant			
First Name	Last Name	That vidual wild is no	Suffix	~ ⁻ ~	inst Name	as a 100	oyist ioi	Last Nam				
			J.	3				,	•			
			*	4								
∃ ISSUE UPDATE		- .										
	iccus that no lon	rar nartain										
24. General lobbying	issue that no ion	ger pertain					[7 6		
			<u> </u>									
AFFILIATED OR	GANIZATIONS	5										
25. Add the following	g affiliated organi	zation(s)										
			A	idres	s				D. C. C. L.	DI		
Nam	e	Street Address	offeet Address (c)							rincipal Place of Bu city and state or co		
		City	;	State/F	rovince Z	ip	Country					
								City			_	
								State		(Count	
								City			_	
								State			Count	
26. Name of each pre	viously reported	_	no longe	er afi	filiated w	ith the	- T	it or cl	ient			
		2					3					
FOREIGN ENTIT	IES											
27. Add the followin	g foreign entities								_			
		Address			Principal place of business				Amount of contribution			
Name	Street Addi City	ess State/Province	Country	ŀ	-	i state or			for lobbying			
			Country	 				-				
Novartis AG	ł ·	sse 35 WSJ		į.	y Basel	_			.00			
	Basel		SUI	Sta		Count						
28. Name of each previo	usly reported foreign	entity that no longer o	wns, or c	ontrol	ls, or is affi	iliated w		zistrant	, client or a	ffiliate	d org	
.] ¬		3					5					
		4					6					

v5.0.0j

Paj